Details for Patent: 12,016,857
Which drugs does patent 12,016,857 protect, and when does it expire?
Patent 12,016,857 protects VIGAFYDE and is included in one NDA.
This patent has three patent family members in two countries.
Summary for Patent: 12,016,857
| Title: | Stable liquid vigabatrin pharmaceutical composition for oral dosage |
| Abstract: | This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin. |
| Inventor(s): | Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal |
| Assignee: | Liqmeds Worldwide Ltd |
| Application Number: | US18/311,126 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Recent additions to Drugs Protected by US Patent 12,016,857
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pyros Pharms | VIGAFYDE | vigabatrin | SOLUTION | 217684 | Jun 17, 2024 | RX | Yes | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,016,857
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pyros Pharms | VIGAFYDE | vigabatrin | SOLUTION;ORAL | 217684-001 | Jun 17, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,016,857
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| United Kingdom | 202103724 | ⤷ Start Trial | |||
| United Kingdom | 2591389 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2020039262 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
